Clinical Trial Update: Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009) [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update states that the Phase 1/2 MK-1022-009 study of patritumab deruxtecan, in combination with other anticancer agents, for HER2-positive …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Patritumab Deruxtecan (patritumab deruxtecan)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Breast Neoplasms, Breast Cancer | Phase 1, Phase 2 | Status: RECRUITING